Related Experiment Videos
Combined modality therapy for pancreatic cancer
James Y Tsai1, David A Iannitti, Howard Safran
1Brown University Oncology Group, Providence, RI, USA.
Seminars in Oncology
|August 9, 2003
Summary
Multimodality therapy, including chemotherapy and radiation, improves outcomes for pancreatic cancer patients. Advanced treatments like chemoradiation and adjuvant gemcitabine are enhancing survival and locoregional control.
Area of Science:
- Oncology
- Gastroenterology
- Medical Oncology
Background:
- Pancreatic cancer has high mortality rates, necessitating advancements in treatment strategies.
- Multimodality therapy is crucial for managing pancreatic cancer.
- Significant progress is being made in improving patient outcomes.
Purpose of the Study:
- To review multimodality therapy approaches for pancreatic cancer.
- To highlight advancements in chemotherapy and radiation combinations.
- To discuss the role of neoadjuvant and adjuvant treatments.
Main Methods:
- Review of phase II trials and Gastrointestinal Tumor Study Group results.
- Analysis of radiosensitizing chemotherapy agents (5-fluorouracil, gemcitabine, paclitaxel, cisplatin).
- Evaluation of chemoradiation for downstaging locally advanced disease and adjuvant therapy (Radiation Therapy Oncology Group study 97-04).
Main Results:
- Chemotherapy combined with radiation improves locoregional control and survival in locally advanced pancreatic cancer.
- Radiosensitizing agents show promise in clinical trials.
- Neoadjuvant chemoradiation can facilitate surgical resection and potentially spare unnecessary surgery.
- Gemcitabine is a key component of adjuvant therapy for resectable disease.
Conclusions:
- Multimodality therapy, particularly chemoradiation, offers improved outcomes for pancreatic cancer.
- Neoadjuvant chemoradiation can optimize treatment sequencing and surgical candidacy.
- Ongoing research combines molecular agents with chemoradiation to prevent systemic progression.